TriSalus Life Sciences® seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational …

Our Company TriSalus Life Sciences ® was established to develop and commercialize disruptive drug delivery technology for the treatment of liver and pancreatic tumors.

TriSalus is focused on improving the response rates in tumors of the liver and pancreas by studying an innovative platform that integrates immunomodulation therapy with proprietary …

2 days ago · TriSalus Senior Director of Pharmacology and Therapeutics, Thomas Hullinger, presented pre-clinical data on the delivery of investigational SD-101 into pig liver tumors via …

TriSalus takes an integrated approach tailored to the target organ and disease biology, with the goal to overcome two critical barriers: immunosuppression and delivery.

Contact TriSalus for general inquiries, investor relations, sales support, clinical trials information, and media relations.

January 13, 2020–TriSalus™ Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav™ Infusion …

The TriSalus™ investigational platform delivers a novel therapeutic (nelitolimod (also known as SD-101)) directly to the site of disease using a proprietary pressure-enabled infusion method.

TriSalus team members and our recruiting team only communicate with potential candidates through an official TriSalus email address ending in “@trisaluslifesci.com”.

TriSalus is investigating nelitolimod (also known as SD-101) as a therapeutic candidate to re-activate the immune system within the liver and pancreas and to enable deeper and more …